$0.45
0.79% yesterday
NYSE, Oct 20, 10:10 pm CET
ISIN
US9286611077
Symbol
VNRX

VolitionRX Stock price

$0.45
-0.17 27.22% 1M
-0.03 6.34% 6M
-0.15 25.38% YTD
-0.28 38.76% 1Y
-1.33 74.85% 3Y
-2.79 86.18% 5Y
-4.09 90.14% 10Y
+0.05 11.93% 20Y
NYSE, Closing price Mon, Oct 20 2025
+0.00 0.79%
ISIN
US9286611077
Symbol
VNRX

Key metrics

Basic
Market capitalization
$53.3m
Enterprise Value
$61.9m
Net debt
$8.5m
Cash
$2.3m
Shares outstanding
104.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
40.4 | 10.2
EV/Sales
46.9 | 11.8
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-265.0%
Return on Equity
108.3%
ROCE
4,346.2%
ROIC
-
Debt/Equity
-0.3
Financials (TTM | estimate)
Revenue
$1.3m | $5.2m
EBITDA
$-22.2m | $-15.7m
EBIT
$-23.5m | $-18.7m
Net Income
$-23.3m | $-20.6m
Free Cash Flow
$-21.8m
Growth (TTM | estimate)
Revenue
34.7% | 325.5%
EBITDA
29.3% | 39.0%
EBIT
28.4% | 30.7%
Net Income
28.1% | 23.7%
Free Cash Flow
-21.9%
Margin (TTM | estimate)
Gross
-
EBITDA
-1,682.4% | -300.0%
EBIT
-1,778.9%
Net
-1,767.8% | -393.1%
Free Cash Flow
-1,651.9%
More
EPS
$-0.3
FCF per Share
$-0.2
Short interest
0.4%
Employees
85
Rev per Employee
$10.0k
Show more

Is VolitionRX a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

VolitionRX Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a VolitionRX forecast:

9x Buy
82%
2x Hold
18%

Analyst Opinions

11 Analysts have issued a VolitionRX forecast:

Buy
82%
Hold
18%

Financial data from VolitionRX

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
1.32 1.32
35% 35%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 13 13
17% 17%
1,000%
- Research and Development Expense 10 10
37% 37%
781%
-22 -22
29% 29%
-1,682%
- Depreciation and Amortization 1.27 1.27
7% 7%
96%
EBIT (Operating Income) EBIT -23 -23
28% 28%
-1,778%
Net Profit -23 -23
28% 28%
-1,767%

In millions USD.

Don't miss a Thing! We will send you all news about VolitionRX directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

VolitionRX Stock News

Neutral
PRNewsWire
4 days ago
HENDERSON, Nev. , Oct. 17, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), and its subsidiary, Volition Veterinary Diagnostics Development LLC, in line with their corporate social responsibility strategy announces participation at the HOPE Animal-Assisted Crisis Response Dogs (HOPE AACR) Annual Conference in Virginia Beach.
Neutral
PRNewsWire
11 days ago
HENDERSON, Nev. , Oct. 10, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today the pricing of an underwritten public offering of 11,550,000 shares of its common stock and warrants to purchase up to 11,550,000 shares of its common stock.
Neutral
PRNewsWire
12 days ago
HENDERSON, Nev. , Oct. 9, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that it is proposing to offer and sell, in an underwritten public offering, shares of its common stock and accompanying common stock purchase warrants.
More VolitionRX News

Company Profile

VolitionRX Ltd. engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluids. The company was founded on September 24, 1998 and is headquartered in Henderson, NV.

Head office United States
CEO Cameron Reynolds
Employees 85
Founded 1998
Website volition.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today